StemBioSys Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$71.8K
- Investors
-
7
StemBioSys General Information
Description
Developer of cell-matrix technologies designed for the enhanced isolation, growth, and delivery of stem cells or other difficult-to-culture cells for research, diagnostic, and therapeutic applications. The company's advanced stem cell culture system replicates the 3-dimensional environment in which stem cells naturally reside and proliferate while remaining small, proliferative, and undifferentiated. enabling healthcare professionals to provide therapeutics to patients for diseases such as adipose, bone marrow, umbilical cord blood, tissue, and cancer cells.
Contact Information
Website
www.stembiosys.comCorporate Office
- 3463 Magic Drive
- Suite 110
- San Antonio, TX 78229
- United States
Corporate Office
- 3463 Magic Drive
- Suite 110
- San Antonio, TX 78229
- United States
StemBioSys Timeline
StemBioSys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Equity Crowdfunding | 05-Sep-2024 | $71.8K | Completed | Generating Revenue | ||
| 10. Grant | 03-Mar-2023 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series C) | 30-Sep-2021 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 08-Dec-2020 | Cancelled | Generating Revenue | |||
| 7. Debt - PPP | 08-Apr-2020 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 09-Jan-2020 | Cancelled | Generating Revenue | |||
| 5. Later Stage VC (Series B) | 15-May-2018 | Completed | Generating Revenue | |||
| 4. Grant | 01-Jan-2018 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 19-Sep-2017 | $10.4M | Completed | Generating Revenue | ||
| 2. Later Stage VC (Series A) | 01-Apr-2015 | $8M | $10.4M | Completed | Startup |
StemBioSys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 4,000,000 | $0.100000 | 5% | $2 | $2 | 1x | $2 | 27.91% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
StemBioSys Comparisons
Industry
Financing
Details
StemBioSys Competitors (8)
One of StemBioSys’s 8 competitors is Stemedica, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Stemedica | Venture Capital-Backed | San Diego, CA | ||||
| Jasper Therapeutics | Formerly VC-backed | Redwood City, CA | ||||
| CellPhire Therapeutics | Venture Capital-Backed | Rockville, MD | ||||
| Vitro Biopharma | Formerly VC-backed | Denver, CO | ||||
| Fate Therapeutics | Formerly VC-backed | San Diego, CA |
StemBioSys Patents
StemBioSys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3130860-A1 | Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds | Pending | 21-Feb-2019 | ||
| EP-3927814-A1 | Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds | Pending | 21-Feb-2019 | ||
| JP-2023076502-A | Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds | Active | 21-Feb-2019 | ||
| JP-2024144465-A | Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds | Active | 21-Feb-2019 | ||
| US-11220671-B2 | Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds | Active | 21-Feb-2019 | C12N5/0657 |
StemBioSys Signals
StemBioSys Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Barshop Ventures | Family Office | Minority | ||
| BioBridge | Investment Bank | Minority | ||
| Fountainhead Biomedical Holdings | Venture Capital | Minority | ||
| U.S. Department of Health and Human Services | Government | |||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | Minority |
StemBioSys Acquisitions (1)
StemBioSys’s most recent deal was a Merger/Acquisition with CarTox. The deal was made on 08-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CarTox | 08-Jan-2020 | Merger/Acquisition | Decision/Risk Analysis |
StemBioSys FAQs
-
When was StemBioSys founded?
StemBioSys was founded in 2010.
-
Where is StemBioSys headquartered?
StemBioSys is headquartered in San Antonio, TX.
-
What is the size of StemBioSys?
StemBioSys has 11 total employees.
-
What industry is StemBioSys in?
StemBioSys’s primary industry is Biotechnology.
-
Is StemBioSys a private or public company?
StemBioSys is a Private company.
-
What is the current valuation of StemBioSys?
The current valuation of StemBioSys is .
-
What is StemBioSys’s current revenue?
The current revenue for StemBioSys is .
-
How much funding has StemBioSys raised over time?
StemBioSys has raised $21.7M.
-
Who are StemBioSys’s investors?
Barshop Ventures, BioBridge, Fountainhead Biomedical Holdings, U.S. Department of Health and Human Services, and Johnson & Johnson Innovation - JLABS are 5 of 7 investors who have invested in StemBioSys.
-
Who are StemBioSys’s competitors?
Stemedica, Jasper Therapeutics, CellPhire Therapeutics, Vitro Biopharma, and Fate Therapeutics are some of the 8 competitors of StemBioSys.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process